Showing 1291-1300 of 3001 results for "".
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
- Study Assesses Biological Age Acceleration in People with Multiple Sclerosishttps://practicalneurology.com/news/study-assesses-biological-age-acceleration-in-people-with-multiple-sclerosis/2470415/Analysis of interim results from a study assessing biological aging in individuals with multiple sclerosis (MS) showed an increase in epigenetic age acceleration (EAA) in a subset of people with secondary progressive MS. The results were presented at the ninth annual Americas Committee for Treatm
- Ketogenic Diet May Reduce Disability and Improve Quality of Life in Multiple Sclerosishttps://practicalneurology.com/news/ketogenic-diet-may-reduce-disability-and-improve-quality-of-life-in-multiple-sclerosis/2469842/A preliminary study found that a ketogenic diet may be safe for people with multiple sclerosis (MS) and reduce fatigue, depression, and disability. Improved quality of life may also occur with a ketogenic diet for people with MS. During the study, 83% of participants adhered to a
- Interim Data Suggest Clinical Improvement Occurring With Nanocrystalline Gold Treatment of Multiple Sclerosishttps://practicalneurology.com/news/interim-data-suggest-clinical-improvement-occurring-with-nanocrystalline-gold-treatment-of-multiple-sclerosis/2469837/Updated interim data from 2 Phase 2 clinical trials support CNM-Au8, a catalytically active gold nanocrystal suspension, as a potential disease-modifying therapy for multiple sclerosis (MS). Data from the Phase 2 VISIONARY-MS study (NCT03536559) suggest treatment with nanocrystal
- Relapses in Multiple Sclerosis Significantly Increased Likelihood of Disability Worseninghttps://practicalneurology.com/news/relapses-in-multiple-sclerosis-significantly-increased-likelihood-of-disability-worsening/2469833/A new study published in Brain has revealed detailed information on how individuals with multiple sclerosis (MS) acquire disability. In retrospective analysis of observational and randomized controlled clinical trials that included over 27,000 individuals with MS, progression inde
- Different Antibody Response to COVID-19 Vaccine With Different Disease-Modifying Therapies for Multiple Sclerosishttps://practicalneurology.com/news/different-antibody-response-to-covid-19-vaccine-with-different-disease-modifying-therapies-for-multiple-sclerosis/2469722/A new analysis of data from the MS PATHS network showed immune response to the COVID-19 vaccine among people with multiple sclerosis (MS) varied with disease-modifying type. These data were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (
- New Multiple Sclerosis Registry Launcheshttps://practicalneurology.com/news/new-multiple-sclerosis-registry-launches/2469648/A technology company with a focus on chronic diseases (OMI; Boston, MA) has launched a multiple sclerosis (MS) registry. The OMI MS registry is a continually updating database of more than 20,000 patients prospectively followed with deep clinical, laboratory, and other data such
- Ublituximab Treatment Lessened Disability for People With Multiple Sclerosishttps://practicalneurology.com/news/ublituximab-treatment-lessened-disability-for-people-with-multiple-sclerosis/2469565/Treatment of people with relapsing multiple sclerosis (MS) with ublituximab (UTX)(TG Therapeutics; New York, NY) slowed progression of MS as measured with biomarkers and disability progression. Compared with teriflunomide (TFM), ublituximab reduced annualized rate of relapse (ARR), gadolinium enh
- Prescription Patterns in Multiple Sclerosis Changinghttps://practicalneurology.com/news/prescription-patterns-in-multiple-sclerosis-changing/2469504/Neurologists are prescribing more oral disease-modifying therapy (DMT) for initial treatment of multiple sclerosis (MS) than ever. Out of 1,018 individuals with multiple sclerosis (MS) in a 3-month period, close to half received an oral DMT as their first treatment. Only 4 years ago, the proporti
- Multiple Sclerosis Does Not Increase Risk of Contracting COVID-19, But Some Treatments, EDSS, and Progressive Status May Increase COVID-19 Severityhttps://practicalneurology.com/news/multiple-sclerosis-does-not-increase-risk-of-contracting-covid-19-but-some-treatments-edss-and-progressive-status-may-increase-covid-19-severity/2469386/In an encore session of MS Virtual 2020, the joint American and European Committees on Treatment and Research in Multiple Sclerosis (ACTRIMS/ECTRIMS) online meeting, new data regarding SARS-COV2 infection rates in people with MS were reported. Effects of disease-modifying treatments for multiple